<DOC>
	<DOCNO>NCT02676349</DOCNO>
	<brief_summary>This prospective , randomized phase II trial . The aim study assess efficacy two therapeutic strategy . Patients borderline-resectable pancreatic cancer ( BRPC ) randomly two arm : neoadjuvant mFolfirinox follow without preoperative chemoradiotherapy capecitabine .</brief_summary>
	<brief_title>Neoadjuvant mFolfirinox With Without Preoperative Concomitant Chemoradiotherapy Patients With Borderline Resectable Pancreatic Carcinoma ( PANDAS-PRODIGE 44 )</brief_title>
	<detailed_description>Surgery , especially follow adjuvant chemotherapy , offer chance cure pancreatic cancer . At first diagnosis , careful assessment , 10 15 % patient consider candidate surgical resection 7 % potentially resectable disease . These potentially resectable tumor call `` borderline resectable pancreatic cancer '' ( BRPC ) conceptualize involve mesenteric vasculature limit extent resection , possible , would likely compromise positive surgical margin ( R1 ) absence neoadjuvant treatment . R0 resection indeed consider independent prognostic factor survival surgical procedure , histological examination definition microscopic invasion standardize . The objective neoadjuvant treatment BRPC reduce tumor volume surgery order improve chance radical ( R0 ) resection reduce rate lymph node positivity recurrence . The primary outcome publish study usually R0 resection rate , result also depend number margin examine definition microscopic margin involvement . Prospective study consistent selection criterion standardize assessment criterion need . Different neoadjuvant therapeutic strategy test pilot study : preoperative chemoradiotherapy neoadjuvant chemotherapy , follow preoperative ( chemo ) radiotherapy . Due lack randomized study , best sequence treatment administration establish . The aim prospective , randomize , multicenter , trial evaluate R0 resection rate neoadjuvant Folfirinox , follow radiochemotherapy patient borderline resectable pancreatic cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>ECOG performance status 0 1 Adult patient ≥ 18 year ≤ 75 year age Histologic cytologic proven adenocarcinoma pancreas ( histologic confirmation diagnosis prefer ) Confirmation independent multidisciplinary expert review borderline resectable status , accord NCCNClinical Practice Guidelines Oncology `` pancreatic adenocarcinoma '' , version 1.2015 . Adequate hematologic function , follow : absolute neutrophil count ( ANC ) ≥ &gt; 2000/mm3 platelet count ≥ 100 000/mm3 haemoglobin ≥ 10 g/dL Adequate renal , hepatic bone marrow function , define : Calculated creatinine clearance ≥ 50 mL/min accord MDRD formula Serum total bilirubin ≤ 1.5 time institutional upper limit normal . Patients biliary short metal stent due cancer obstruction may include provided highquality image perform stenting bilirubin level stent insertion decrease ≤ 20 mg/L ( ≤ 34 µmol/l ) , cholangitis . Male female subject agree use highly effective method birth control ( e.g. , condom , combine oral contraceptive , intrauterine device [ IUDs ] , sexual abstinence , sterilize partner ) male subject : treatment 6 month last dose oxaliplatin 3 month last dose irinotcan . female subject : treatment 4 month last dose oxaliplatin 3 month last dose irinotcan . Ability provide write informed consent start study specific procedures Patient 's legal capacity consent study participation understand comply requirement study . Any previous treatment pancreatic cancer except biliary short metal stenting ( chemotherapy , target tumor therapy , local ablative therapy , previous irradiation within actual field plan radiotherapy ) Evidence distant metastasis include ascites Evidence extent pancreatic cancer beyond define `` borderline resectable '' : suspicious lymphadenopathy outside standard field resection ( i.e. , aortocaval node , distant abdominal node ) Contraindication pancreas resection Pregnant breast feeding female Patients know Gilbert 's Syndrome homozygosity UGT1A1*28 polymorphism Participation clinical trial treatment experimental drug within 28 day enrolment study study participation end treatment visit . Previous concurrent malignant tumor disease underlie tumor disease ( exception cervical cancer situ , adequately treat nonmelanoma skin cancer , superficial bladder tumor ( Ta , Tis , T1 ) curatively treat without chemotherapy favourable prognosis tumor without evidence disease &gt; 3 year prior enrolment ) Any severe and/or uncontrolled medical condition include limited : Clinically significant cardiovascular vascular disease : angina pectoris ( even control ) , previous myocardial infarction , serious uncontrolled cardiac arrhythmia , chronic heart failure , cerebral infarction ) Acute chronic , active infectious disorder require systemic treatment Peripheral polyneuropathy &gt; grade 1 Any previous inflammatory disease colon rectum Any severe concomitant disease disorder , could influence patient 's ability participate study his/her safety study e.g . severe hepatic , renal , pulmonary , metabolic , psychiatric disorder Hypersensitivity study drug ( gemcitabine , oxaliplatin , irinotecan , 5fluorouracil , folinic acid ) , ingredient drug ( e.g . fructose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mFolfirinox</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Neoadjuvant treatment</keyword>
	<keyword>Borderline</keyword>
</DOC>